RT Journal Article SR Electronic T1 An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5007 OP 5014 DO 10.21873/anticanres.15315 VO 41 IS 10 A1 TSUTOMU TAKASHIMA A1 SHIGEHIKO NISHIMURA A1 HIDEMI KAWAJIRI A1 YOKO MIZUYAMA A1 TAKEO NISHIMORI A1 SHIGEHITO YAMAGATA A1 SHINYA TOKUNAGA A1 KENJI TEZUKA A1 SEIKA TEI A1 TAKESHI SUNAMI A1 KATSUMI IKEDA A1 YOSHINARI OGAWA A1 SHINICHIRO KASHIWAGI A1 SATORU NODA A1 NAOYOSHI ONODA A1 TETSURO ISHIKAWA A1 SHINZOH KUDOH A1 MINORU TAKADA A1 KOSEI HIRAKAWA A1 MASAICHI OHIRA YR 2021 UL http://ar.iiarjournals.org/content/41/10/5007.abstract AB Background/Aim: In our previous study, first-line eribulin (ERI) showed 25 weeks of progression-free survival (PFS). This study investigated the efficacy and safety of ERI re-administration in metastatic breast cancer (MBC) patients. Patients and Methods: HER2-negative MBC patients who had never received chemotherapy for MBC received first-line ERI for 18 weeks if they did not have disease progression, and then one cycle of S-1 before ERI re-administration. Results: Twelve patients received ERI re-administration. The PFS of re-administered ERI was 13 weeks. Total duration of ERI use was 30 weeks. The incidence and severity of adverse events were consistent with previous reports. Conclusion: In the first-line setting, the total PFS of eribulin was extended by S-1 administration before disease progression, compared with that of our previous report.